$1-per-pill alternative to Turing drug gets 'overwhelming' response: Imprimis CEO

Imprimis ($IMMY) CEO Mark Baum says response has been "overwhelming" to his company's $1-per-pill alternative to toxoplasmosis drug Daraprim, from the now-notorious Turing Pharmaceuticals, which raised its pill price to $750 each from $13.50 earlier this year. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Stinging from a previous trial failure in 2016, AstraZeneca's Brilinta topped solo aspirin in slicing CV risks in heart attack and stroke patients.

Taking over IL-23 inhibitor brazikumab marks a new endeavor for AstraZeneca, as does buying prescription drugs Zenpep and Viokace for Nestlé.